# Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

> **NCT05997277** · PHASE2 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Deucravacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05997277
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-30
- **Primary completion:** 2025-02-25
- **Final completion:** 2025-04-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Funding withdrawn by sponsor due to funding priorities, study cannot continue without funding
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05997277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05997277, "Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05997277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*